We are a seed-stage biotech company dedicated to relentlessly pursuing functional cures for rare disease patients and their families. With an initial focus on rare diseases, we aim to expand our scope to include genetically defined common diseases in the future.

Jantar is a clinical R/D company in the field of chronic rhinosinusitis. Its asset is dicholine succinate for which clinical proof-of-concept has been established. DISU represents a differentiated new drug with strong safety, rapid efficacy and clear potential for global consumer health leadership.